Ainos, Inc. reported financial results for the quarter ended June 30, 2026. The company generated $152 in revenue and incurred a net loss of $4,594,731, or $0.62 per share. Cash and cash equivalents increased to $1,422,912 from $417,353 at year-end 2025. The company advanced deployments for a previously announced $2.1 million commercial arrangement in semiconductor manufacturing and expanded pilot programs across industrial, healthcare, and robotics sectors. Ainos operates in the artificial intelligence and biotechnology industries, developing an electronic nose platform called AI Nose and immune therapeutics.